Clinicopathological characteristics of progressive gastrointestinal stromal tumors and heterogeneity analyses of secondary mutations
The Oncologist · 2025
DOI: 10.1093/oncolo/oyaf110 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Oncologist, 2025. Verfasst von Jiaxin Li und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, Tianjin Medical University Cancer Institute & Hospital, National Clinical Research Center for Cancer, Tianjin's Clinical Res…. Hauptthemen laut MEDLINE: Gastrointestinal Stromal Tumors, Mutation, Gastrointestinal Neoplasms. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Key Project in 14th Five-Year Plan Special for Cancer Prevention, Treatment Research from Tianjin Cancer Institute.
Abstract (Originalsprache)
Background
Although there have been multiple lines of drugs for gastrointestinal stromal tumors (GISTs), the drug response depends on the progressive tumors’ biological behaviors and secondary mutations.
Methods
We investigated the primary and secondary mutations in multiple tumors from the same patients and at multiple regions from the same tumor to analyze the inter- and intratumoral heterogeneities using Sanger sequencing and next-generation sequencing (NGS).
Results
Secondary mutations were more frequently detected in patients with a targeted therapy history and who continued their targeted therapy until surgery or biopsy, in larger tumors, and in tumors located in the intestine, abdominal cavity, and mesentery. Secondary mutations were detected in only 57.5% of the samples from the cases with secondary mutations, and 34.8% of the cases presented multiple types of secondary mutations, including both intertumoral and intratumoral heterogeneities. Temporal heterogeneity was also observed at different time points of progression. The results of NGS and Sanger sequencing were consistent for the individual sample, but Sanger sequencing detected multiple types of secondary mutations from different tumors of the same patient. Liquid biopsy also only detected partial secondary mutations revealed by Sanger sequencing.
Conclusion
Progressive GISTs had intertumoral and intratumoral heterogeneities of secondary mutations. Sanger sequencing had its own advantage in revealing the heterogeneity of secondary mutations. The improvement in the detection rate of secondary mutations by selecting the appropriate tumor sample to be tested, or even the appropriate tumor region or test method, is helpful to identify the optimal drugs for progressive GISTs.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Pathology, Tianjin Medical University Cancer Institute & Hospital, National Clinical Research Center for Cancer, Tianjin's Clinical Research Center for Cancer, Tianjin Key Laboratory of Digestive Cancer, T…
- Department of Gastric Surgery, Tianjin Medical University Cancer Institute & Hospital, National Clinical Research Center for Cancer, Tianjin's Clinical Research Center for Cancer, Tianjin Key Laboratory of Digestive Can…
ORCID-Profile: Yan Sun
Förderung
- National Natural Science Foundation of China
- Key Project in 14th Five-Year Plan Special for Cancer Prevention
- Treatment Research from Tianjin Cancer Institute
- Construction Project of Cancer Precision Diagnosis
- Drug Treatment Technology from TUCIH
- Tianjin Key Medical Discipline (Pathology) Construction Project
- Scientific Research Project from Tianjin Education Commission
Zitieren
APA
Li, J., Sun, L., Liu, S., Liu, H., Li, B., Zhan, H., & Sun, Y. (2025). Clinicopathological characteristics of progressive gastrointestinal stromal tumors and heterogeneity analyses of secondary mutations. The Oncologist. https://doi.org/10.1093/oncolo/oyaf110
Vancouver
Li J, Sun L, Liu S, Liu H, Li B, Zhan H, et al. Clinicopathological characteristics of progressive gastrointestinal stromal tumors and heterogeneity analyses of secondary mutations. The Oncologist. 2025. doi:10.1093/oncolo/oyaf110
BibTeX
@article{Li2025,
author = {Li, Jiaxin and Sun, Lin and Liu, Shasha and Liu, Huimin and Li, Bin and Zhan, Hongjie and Sun, Yan},
title = {Clinicopathological characteristics of progressive gastrointestinal stromal tumors and heterogeneity analyses of secondary mutations},
journal = {The Oncologist},
year = {2025},
doi = {10.1093/oncolo/oyaf110}
}
EUVIMED